Nuclear medicine company Curium confirmed in a recent statement that it doesn't expect supply challenges of its lutetium-177 (Lu-177) prostate-specific membrane antigen (PSMA) with 3-iodo-D-tyrosine (I&T) for the company's Eclipse phase III clinical trial.
The trial is ongoing in the U.S., France, Spain, and Italy. Since patient enrollment started in March 2022, the trial has experienced what the company says is "reliable and uninterrupted" supply of the radiotherapy.
Eclipse is a phase III, multicenter, open-label, randomized clinical trial comparing the safety and efficacy of Lu-177 PSMA-I&T versus hormone therapy in patients with metastatic castration-resistant prostate cancer.
